Is there a vascular side of the story? Vascular consequences during COVID ‐19 outbreak in Lombardy, Italy

ConclusionCOVID ‐19 infection seems to be not only a pulmonary but also a vascular (arterial and venous) disease. Further study are necessary to described mid and long‐term outcomes in COVID‐19 vascular patients population.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: A REVIEW ARTICLE Source Type: research

Related Links:

Hopefully, we will someday be united again – if not on issues, at least on the facts, writes guest columnist Stan Silverman.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Conclusions The present RCT of a tailored center-based HIIT intervention provides preliminary evidence that this intervention could improve exercise capacity, lung function, RV function, and HRQoL without serious adverse events, which could provide marked clinical benefits after PE. Further larger multicenter randomized controlled studies are needed to confirm these promising findings.
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: CLINICAL SCIENCES Source Type: research
No abstract available
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: SPECIAL COMMUNICATIONS: Letters to the Editor-in-Chief Source Type: research
The Durham company is committing $100 million to advance a combination therapy aimed at treating Covid-19 following positive results from a trial sponsored by the National Institutes of Health.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
ConclusionCOVID ‐19 infection seems to be not only a pulmonary but also a vascular (arterial and venous) disease. Further study are necessary to described mid and long‐term outcomes in COVID‐19 vascular patients population.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Special Section: Cardiac Surgery Amid COVID 19 Source Type: research
The outbreak of the coronavirus disease 2019 (COVID-19) spread rapidly throughout the world during the first months of 2020 reaching the pandemic status as a major global health issue. The main clinical and therapeutic concerns due to COVID-19 relate to the respiratory distress and failure caused by pneumonia due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19, however, is not just a pulmonary disease. While respiratory complications and systemic inflammation unquestionably result in significantly higher morbidity and mortality rates, cardiovascular complications are also common [2].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
This study provides the largest overview of autopsies of SARS-CoV-2-infected patients presented so far.
Source: International Journal of Legal Medicine - Category: Medical Law Source Type: research
The outbreak of novel coronavirus disease 2019 (COVID-19) in the city of Wuhan, Hubei Province, China, was declared a pandemic by the World Health Organization (WHO) on March 21, 2020. Since then, this outbreak has forced the scientific community to consider two fundamental aspects: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, does not only cause pneumonia, and the death of many critically ill patients is caused by multiple organ failure (involving the heart, liver, kidneys, blood, and immune system) (Wang et al., 2020).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Letter to the editor Source Type: research
More News: Cardiovascular & Thoracic Surgery | Coronavirus | COVID-19 | Italy Health | Outbreaks | Pandemics | Pulmonary Thromboembolism | Study | Thrombosis